Sana Biotechnology

Sana Biotechnology, based in Seattle and listed as SANA, is a hypoimmune cell therapy company that suspended its oncology allogeneic CAR-T, SC262, in late 2025 and pivoted to type 1 diabetes and in vivo CAR-T. SC262, a CD22 allogeneic CAR-T, had its development suspended and VIVID trial enrolment halted in November 2025; SG293 is a fusogen-delivered CD19 in vivo CAR-T candidate for oncology and autoimmunity, and SC451 islet cells lead its diabetes work. OnCo links it to diffuse large B-cell lymphoma, to allogeneic cell therapy and in vivo CAR-T, to CD19 as a target, and to the idea of qualifying one iPSC master cell bank once for many off-the-shelf products. Manufacturing cost and time for living medicines is the bottleneck behind its shift from ex vivo to in vivo approaches. Whether fusogen delivery works in patients is the open question.